Nova Scotia Lists EPCLUSA™ on Public Drug Plan to Treat All Six Genotypes of Chronic Hepatitis C Infection

Short resume:

information
80%
privacy
80%
create
70%
please
70%

MISSISSAUGA, ON, May 1, 2017 /CNW/ – Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective immediately, Nova Scotia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single …
Source Ottawa Citizen
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*